Render Target: STATIC
Render Timestamp: 2025-03-14T10:38:03.350Z
Commit: a619ae74f66dae0f27639e88da12bcf600e46428
XML generation date: 2025-03-07 13:06:53.670
Product last modified at: 2025-03-06T19:45:09.695Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

LIMD1 Antibody #13245

Filter:
  • WB

    Supporting Data

    REACTIVITY H M
    SENSITIVITY Endogenous
    MW (kDa) 72
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    LIMD1 Antibody recognizes endogenous levels of total LIMD1 protein. This antibody cross-reacts with a protein of unknown origin at ~45 kDa.

    Species Reactivity:

    Human, Mouse

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human LIMD1 protein. Antibodies are purified by protein A and peptide affinity chromatography.

    Background

    LIM domain-containing protein 1 (LIMD1) is a putative tumor suppressor and adapter/scaffold protein that belongs to the Ajuba family of LIM domain containing proteins. LIM domain containing proteins mediate protein-protein interactions and typically contain a pair of distinct zinc finger domains (1). Research studies indicate that LIMD1 is involved in numerous cellular processes, including inhibition of E2F mediated transcription (2) and negative regulation of the Hippo pathway through influence on YAP phosphorylation state (3,4). Additional studies identify LIMD1 as a hypoxia regulator as it recruits the Von Hippel-Lindau (VHL) protein and the hydroxylase PHD1 to a protein complex that promotes initiation of HIF-1α ubiquitination and degradation (5). Research evidence supporting the role of LIMD1 as a tumor suppressor includes the down regulation of the protein in 80% of lung cancers (6), loss of LIMD1 expression in head and neck cancers (7), and altered subcellular localization in cases of breast cancer (8).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.